Compare Equitable Holdings Inc. Common Stock (EQH) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equitable Holdings Inc. Common Stock vs Invesco Ltd. — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.49B), while Invesco Ltd. trades at $27.87 (market cap $12.77B). The key difference: Equitable Holdings Inc. Common Stock and Invesco Ltd. are close in size by market cap, and Invesco Ltd. pays the higher dividend (2.97%). Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and Invesco Ltd. for 77 Days on average.
| EQH | IVZ | |
|---|---|---|
Market Cap | $14.49B | $12.77B |
Volume | 2,405,401 | 2,758,656 |
Sector | Financials | Financials |
52-Week High | $54.50 | $33.31 |
52-Week Low | $35.34 | $22.44 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $5.54B | $22.93B |
Dividend Yield | 2.15% | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
Invesco (IVZ) trades at $27.93, down 4.55% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, with a negative net income margin of -0.93%. Recent news highlights product expansions, including the launch of the Invesco Nasdaq International Innovators 100 ETF, and a dividend of $0.22 per share scheduled for September 2026.
The outlook is cautious; analyst consensus is a buy with a $33.17 price target, but profitability challenges and bearish technicals pose risks. Positive cash flow and AUM growth offer potential, yet investors must weigh weak margins against strategic initiatives in a competitive ETF landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
